Overview consensus statement - 03/09/11

Doi : 10.1016/S0090-4295(01)01234-1

Peter R Carroll ^a,^b,⁎ , William R Fair ^c, Gary D Grossfeld ^a, Warren D.W Heston ^d, Ronald Lieberman ^e, S.Bruce Malkowicz ^{^{1
S. Bruce Malkowicz is on the speaker’s bureau of the supporter of this supplement.},}^f,^g, Hans J Stricker ^h, John Sylvester ⁱ, Donna M Peehl ^j, François Meyer ^k, Carol Hart ^l
^a Department of Urology, University of California School of Medicine, San Francisco, California, USA
^b Program in Urologic Oncology, University of California San Francisco/Mount Zion Comprehensive Care Center, San Francisco, California, (PRC, GDG), USA
^c Haelth, LLC, New York, New York, (WRF), USA
^d George M. O’Brien Urology Research Center, Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, (WDWH), USA
^e Prostate and Urologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland, (RL), USA
^f Division of Urology, Department of Surgery, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
^g Philadelphia Veterans Administration Medical Center, Philadelphia, Pennsylvania, (SBM), USA
^h Department of Urology, Henry Ford Hospital, Detroit, Michigan, (HJS), USA
ⁱ Seattle Prostate Institute, Seattle, Washington, (JS), USA
^j Department of Urology, Stanford University School of Medicine, Stanford, California, (DMP), USA
^k Laval University Cancer Research Center, Centre Hospitalier Universitaire de Québec, l’Hôtel-Dieu de Québec, Quebec, Canada (FM)
^l InforMEDical, Inc., Narberth, Pennsylvania, (CH), USA

^*Reprint requests: Peter R. Carroll, MD, U-575, University of California San Francisco Medical Center, 533 Parnassus Avenue, San Francisco, California 94143